Insight Molecular Diagnostics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- In 3rd quarter 2026, R&D expenses were $3.8 million, down from $5.8 million in Q4 2025, when FDA program costs drove the increase.
- Operating expenses less non-cash items were flat with Q3 a year ago, and management said operating expenses and free cash flow trended in the right direction.
- The company began enrolling patients in the Galactic Registry, with UCLA as the first site; management expects about 5 sites to be enrolling by year-end.
- Management said centers representing a little north of 1 in 20 US kidney transplants have committed to in-house testing and are lining up to launch in 2027.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, everyone, and thank you for joining us to discuss Insight Molecular Diagnostics' third quarter 2026 results. If you have not seen today's shareholder letter, please visit imdxinc.com for today's letter. Today's prepared remarks build upon the information already shared in this robust letter. Joining us today are Insight Molecular Diagnostics President and CEO Josh Riggs, Chief Science Officer Ekki Schütz, and CFO Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Before turning the call over to Josh Riggs, I would like to review our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.
We encourage you to review the company's SEC filings, including the company's most recent Form 10-K and subsequent Forms 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note that the forward-looking statements made during today's call speak only to the day that they are made, and Insight Molecular Diagnostics undertakes no obligation to update them. With that, I would like to now turn the call over to Josh Riggs.
Thanks, Gabby. Good afternoon, everybody, and thanks for joining us. Today, I will focus on two main topics, the start of U.S. revenue from GraftAssure and what we believe will be the final steps related to our FDA submission. We have made investment into two areas to drive pre-Dx launch revenue. Admittedly, this revenue stream has taken a little bit longer than we had hoped to get started, but it seems like it is finally ready to begin, namely from the GALACTIC registry and also the beta site program, which I will describe in a moment. Before I get to that, I would like to mention our new Head of Commercial, Donnie Purto. Mr. Purto is an accomplished sales leader with more than 20 years of experience building and leading high-performing sales organizations across diagnostics, life sciences, and healthcare.
During a decade at Natera, he had success in leadership roles spanning sales, training, oncology, transplant, and women's health. He managed new product launches as well as hundreds of millions of dollars in revenue in highly competitive markets. His experience makes him a great fit as we transition out of the development stage towards being fully commercial. We are counting on his leadership to make GraftAssure the leading product in transplant management. On that, I am pleased to announce we have officially started enrolling patients in our GALACTIC registry. Big congratulations to the UCLA team for being the first to enroll. They have been a foundational site for the validation of dd-cfDNA broadly, and we are glad to have them on board as we build the next generation of clinical utility. As a reminder, GALACTIC aims to show the power of having a positive predictive value north of 80%.
Contrast that with current assays clocking at around 50%, which is basically just a coin flip. The expectation is that we will see a higher on-target rate for biopsies. It looks like we are going to have five or so sites enrolling by the end of the year, with more in the hopper for Q1. Enrollment in the GALACTIC study begins a mostly predictable revenue stream, and importantly, it means that the clinical community will gain experience using our GraftAssure tests. Shifting over, for about a year and a half, we have been supporting beta sites across the U.S. The goal was to get centers familiar and comfortable with GraftAssure technology. We have seen a couple head-to-heads come out demonstrating equivalency to legacy tests. This is great for building clinical confidence. Just recently at ASHI, one site showed a turnaround time of just six and a half hours.
That is a significant improvement over the several days it takes to get a send-out test back. Quickly, just in case anyone needs it, ASHI is an annual conference where transplant lab leaders meet to learn about new technology and best practices. Perhaps the most exciting news coming out of that conference is how close transplant centers are to launching in-house dd-cfDNA testing services here in the U.S. It is clear to us that leading labs are no longer intimidated by the idea of bringing testing in-house. A handful of hospital laboratories have completed both analytical and clinical validation and are moving on towards reimbursement. By our count, centers representing a little north of one in 20 U.S. kidney transplants have indicated that they are committed to in-house testing and lining up to launch in 2027.
I expect that this will be a watershed moment in the transition from centralized to local care. The support of ASHI broadly has been great. They continue to make progress on establishing proficiency guidelines, which lays the groundwork for the broad adoption of dd-cfDNA at HLA labs across the U.S. Shifting over to the FDA. In late July, the FDA completed the first phase of its substantive review of GraftAssureDx and requested additional information, which is common for a De Novo submission such as ours. In late September, we met with the FDA to discuss our approach to addressing the additional information request. Known as an SIR meeting, this is a de-risking step to help make sure we have good alignment on expectations. The agency has provided both verbal and written feedback to help guide our next data package.
We are busy finishing up the extra homework they gave us on our way to a final submission. We have two external processes that factor into the timing for our response. The first is an independent study to further demonstrate the accuracy and consistency of our test results. This will bolster our internally generated data. The second is an additional review of biopsy slides, for which we have secured two well-known expert pathologists to establish the diagnoses against which our test results will be evaluated. We currently expect both processes to be completed before the end of the year and to submit our complete response before the January 21st, 2027 deadline that we have. The FDA has a targeted review timeline of 150 days for Class II De Novo submissions. Since we received the additional information request in late July, the review clock has been paused.
We estimate that approximately half of the review days remain, and the clock will restart once we submit. One additional note before I hand the call over to Andrea. We have added GraftAssure urine screening for T-cell-mediated rejection into our pipeline. Missing early TCMR has been one of the biggest drawbacks of today's blood-based tests. We believe that we are the first company to demonstrate the ability to detect early TCMR in urine using a donor-derived cell-free DNA test. We can see a future where docs will order both blood and urine together in the first three years to rule out both main types of rejection, ABMR and TCMR. We believe that this has the opportunity to drive significant growth and demand. This will come alongside our expansion to heart testing in transplant patients in 2027. Now I'll hand over to Andrea to take us through the financials.
Thanks, Josh. Hi, everyone. Okay, so earlier today, we published our robust shareholder letter, and that allows me to keep my prepared remarks relatively short. That was filed as an eight-K right after the close. It took us a minute to get it up online, but hopefully you all had a chance to read it. Regarding our third quarter performance, I want to point out simply that our operating expenses and free cash flow trended in the right direction. Operating expenses peaked in Q4 2025 as we incurred significant expenses associated with our FDA program. As we alluded to last quarter, we believe that cash burn had bottomed in Q2 of 2026, so the most recent quarter behind us, and as we work through some of those payments that were associated with our Q4 GAAP expenses.
That OPEX growth that you saw go through the P&L over the last several quarters was driven largely by our FDA program. OPEX peaked in Q4 2025 when R&D expenses reached $5.8 million, and that's above $2 million above the prior quarter, Q3, and it was driven by lab supplies, consulting, and FDA trial site costs. R&D back down to $3.8 million in the third quarter, and that still includes the remaining work to advance the GraftAssureDx toward authorization. You'll notice in the third quarter that operating expenses, less the non-cash items, were flat with Q3 a year ago. You can really see those FDA program expenses winding down.
As the FDA review concludes, the R&D focus shifts from securing authorization to building out the GraftAssure platform by expanding the menu, which Josh had talked about, and the evidence base so that each transplant center can do more with our technology. Our target is for future FDA programs to be sustained by the gross profit from our kidney transplant assay. Before we go to questions, I thought I'd share what brings me excitement about our trajectory and why, since becoming CFO, I have invested in the company personally, both through capital raises as well as via open market buying. IMDX has many of the hallmarks of companies that enjoy the kind of growth that comes from disrupting a market. The concept of turning a molecular lab test into a kit is a good idea, and you need three ingredients for this idea to be successful.
You need high clinical demand, meaning, will doctors order the test? You need strong reimbursement, meaning, can we get paid? You need the product to be IP protected, meaning we have a right to sell it with a sustainable competitive advantage. iMDx has all three. For high clinical demand, donor-derived cell-free DNA tests are already ordered in the hundreds of thousands of times per year, every year, by clinicians. These same clinicians who order these tests are telling us that they want to do their own testing. As a matter of fact, Josh is sitting with a lot of these potential future customers right now. For reimbursement, we have had Medicare MolDX reimbursement since August 2023 on our Tennessee lab-developed test, and FDA authorization would allow us to port this reimbursement to our customer labs.
Finally, our proprietary digital PCR-based assay is IP protected, and we expect to continue to grow our patent portfolio. We believe that the total addressable market for regulated transplant testing, that is the kit of testing that we seek to sell, is $800 million in the U.S. alone. After kidney, our product pipeline includes expansion into other organs, like heart and lung transplant testing, as well as testing modalities other than blood, specifically urine testing. Our assay performs well out in the field. It has been tested on research-use-only mode for over two years now, and our FDA dialogue has been very rigorous, as expected, but also encouraging. Okay, Gabby, now we can take questions, and I saw some of the hands come up while I was speaking.
Eric, can you put us into gallery mode, please? All right, we will start with Alex Nowak from Lucid.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
